NATERA INC

Explore Natera Inc.’s 2025 earnings and breakthrough Signatera MRD platform—showing 18% revenue growth, 42% gross margin, and clinical data that could shape personalized cancer treatment and reimbursement approvals.

Explore Natera’s high‑accuracy, non‑invasive preconception and prenatal genetic testing—boosting diagnostic precision, reducing invasive procedures, and shaping future reproductive healthcare.

FDA review of Natera’s high‑sensitivity urine test for bladder‑cancer recurrence promises earlier detection, less invasive monitoring, and potential cost savings for patients and payers.

Discover how Natera’s new AI‑driven MRD platform could change oncology care—boosting early relapse detection and tailoring treatment at JHC 2024.

Discover how Natera’s partnership with EXEL aims to expand its liquid‑biopsy portfolio into colorectal cancer diagnostics, tackle reimbursement hurdles, and outpace competitors.

Explore how Natera’s ctDNA platform powers a Phase‑3 colorectal cancer study with Exelixis, boosting oncology diagnostics and investor confidence.

Discover how Natera’s upcoming ALTAIR trial data could reshape cfDNA diagnostics, reimbursement, and healthcare workflows—and what it means for investors.

Discover how Natera’s acquisition of Foresight and Canaccord’s “Buy” rating boost precision diagnostics and investor confidence.

Explore Natera’s market dynamics, growth prospects, and risk factors—an in‑depth look at its liquid biopsy & prenatal testing strategy, competitive landscape, and future outlook.

Discover why Natera’s upgraded stock‑price target reflects its winning cfDNA platform, FDA‑cleared NIPT and oncology liquid biopsies, and future growth plans.